Andrej Zeyfang, Stefan Gölz, Federica Iraci, Christian Wagner, Christian Scheer, Thomas Kubiak, Latife Bozkurt, Martin Heni, Reinhard W Holl
{"title":"老年2型糖尿病患者的抗糖尿病药物处方模式：来自德国DPV登记的结果。","authors":"Andrej Zeyfang, Stefan Gölz, Federica Iraci, Christian Wagner, Christian Scheer, Thomas Kubiak, Latife Bozkurt, Martin Heni, Reinhard W Holl","doi":"10.1016/j.jamda.2025.105724","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To explore prescription patterns of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) in older adults with type 2 diabetes (T2DM), analyzing age and sex differences.</p><p><strong>Design: </strong>Observational retrospective study.</p><p><strong>Setting and participants: </strong>Data from 103,820 patients aged 60 to 90 years from 518 diabetes centers in Germany, collected between 2017 and 2022 via the DPV registry.</p><p><strong>Methods: </strong>Patients with at least 3 months' T2DM diagnosis were included. Treatment trends were analyzed using regression models adjusted for age and sex. Repeated measures were aggregated annually.</p><p><strong>Results: </strong>Between 2017 and 2022, SGLT2i use rose from 7.3% to 27.4% and GLP-1RA use from 3.4% to 13.8%. Metformin use increased, while sulfonylureas declined. SGLT2i use was lower in women across all age groups. GLP-1RAs use increased more in younger patients.</p><p><strong>Conclusions and implications: </strong>Newer antidiabetic drugs are increasingly prescribed in older adults, but notable disparities by age and gender persist. These findings suggest the need to address potential biases and barriers to optimize equitable care in geriatric diabetes management.</p>","PeriodicalId":17180,"journal":{"name":"Journal of the American Medical Directors Association","volume":" ","pages":"105724"},"PeriodicalIF":4.2000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pattern of Antidiabetic Drug Prescription in Older Persons With Type 2 Diabetes: Results From the German DPV Registry.\",\"authors\":\"Andrej Zeyfang, Stefan Gölz, Federica Iraci, Christian Wagner, Christian Scheer, Thomas Kubiak, Latife Bozkurt, Martin Heni, Reinhard W Holl\",\"doi\":\"10.1016/j.jamda.2025.105724\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To explore prescription patterns of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) in older adults with type 2 diabetes (T2DM), analyzing age and sex differences.</p><p><strong>Design: </strong>Observational retrospective study.</p><p><strong>Setting and participants: </strong>Data from 103,820 patients aged 60 to 90 years from 518 diabetes centers in Germany, collected between 2017 and 2022 via the DPV registry.</p><p><strong>Methods: </strong>Patients with at least 3 months' T2DM diagnosis were included. Treatment trends were analyzed using regression models adjusted for age and sex. Repeated measures were aggregated annually.</p><p><strong>Results: </strong>Between 2017 and 2022, SGLT2i use rose from 7.3% to 27.4% and GLP-1RA use from 3.4% to 13.8%. Metformin use increased, while sulfonylureas declined. SGLT2i use was lower in women across all age groups. GLP-1RAs use increased more in younger patients.</p><p><strong>Conclusions and implications: </strong>Newer antidiabetic drugs are increasingly prescribed in older adults, but notable disparities by age and gender persist. These findings suggest the need to address potential biases and barriers to optimize equitable care in geriatric diabetes management.</p>\",\"PeriodicalId\":17180,\"journal\":{\"name\":\"Journal of the American Medical Directors Association\",\"volume\":\" \",\"pages\":\"105724\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Medical Directors Association\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jamda.2025.105724\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Medical Directors Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jamda.2025.105724","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
Pattern of Antidiabetic Drug Prescription in Older Persons With Type 2 Diabetes: Results From the German DPV Registry.
Objectives: To explore prescription patterns of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) in older adults with type 2 diabetes (T2DM), analyzing age and sex differences.
Design: Observational retrospective study.
Setting and participants: Data from 103,820 patients aged 60 to 90 years from 518 diabetes centers in Germany, collected between 2017 and 2022 via the DPV registry.
Methods: Patients with at least 3 months' T2DM diagnosis were included. Treatment trends were analyzed using regression models adjusted for age and sex. Repeated measures were aggregated annually.
Results: Between 2017 and 2022, SGLT2i use rose from 7.3% to 27.4% and GLP-1RA use from 3.4% to 13.8%. Metformin use increased, while sulfonylureas declined. SGLT2i use was lower in women across all age groups. GLP-1RAs use increased more in younger patients.
Conclusions and implications: Newer antidiabetic drugs are increasingly prescribed in older adults, but notable disparities by age and gender persist. These findings suggest the need to address potential biases and barriers to optimize equitable care in geriatric diabetes management.
期刊介绍：
JAMDA, the official journal of AMDA - The Society for Post-Acute and Long-Term Care Medicine, is a leading peer-reviewed publication that offers practical information and research geared towards healthcare professionals in the post-acute and long-term care fields. It is also a valuable resource for policy-makers, organizational leaders, educators, and advocates.
The journal provides essential information for various healthcare professionals such as medical directors, attending physicians, nurses, consultant pharmacists, geriatric psychiatrists, nurse practitioners, physician assistants, physical and occupational therapists, social workers, and others involved in providing, overseeing, and promoting quality
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
